Lin Zhi

This inventor holds 127 USPTO granted patents and 15 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D-). Top assignees: Ligand Pharmaceuticals, Inc., Wyeth, Nucorion Pharmaceuticals, Inc.. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lin Zhi. Retrieved from https://idiyas.com/inventor/lin-zhi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 127 (Patent Applications = 15)

% Patents Active = 71.7

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 25)

Average Co-Inventor Count = 3.0

ph-index = 28

Forward Citations = 2,171(Granted Patents)

Forward Citations (Not Self Cited) = 1,118(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

La Jolla, CA (US) (2013 - 2019)
Austin, TX (US) (2022 - 2023)
San Diego, CA (US) (1997 - 2024)

Company Filing History:

76 out of 139

Ligand Pharmaceuticals, Inc.

Nucorion Pharmaceuticals, Inc.

patents

4. 1 out of 2,198

Smithkline Beecham Corporation

patents

5. 34 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Prodrug Compounds

Selective Androgen Receptor Modulators

Glucagon Receptor Antagonists

Heterocycle Amines

Cyclic Deoxyribonucleotide Compounds

Imidazo-Fused Heterocycles

Granulocyte Colony-Stimulating Factor

Crystalline Forms

Nucleotide Prodrug Compounds

Benzyloxy Phosph(on)ate Compounds

5-Fluorouracil Compounds

Hematopoietic Growth Factor Mimetic

127 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12552820 - Benzyloxy phosph(on)ate compounds (2026-02-17),

2. 12319651 - Crystalline forms and methods of producing crystalline forms of a compound (2025-06-03),

3. 12208071 - Glucagon receptor antagonists (2025-01-28),

4. 12110311 - Cyclic deoxyribonucleotide compounds (2024-10-08),

5. 12110308 - Phosphor(n)amidatacetal and phosph(on)atalcetal compounds (2024-10-08),

6. 11970482 - Acetal compounds and therapeutic uses thereof (2024-04-30),

7. 11858938 - Imidazo-fused heterocycles and uses thereof (2024-01-02),

8. 11773110 - Heterocycle amines and uses thereof (2023-10-03),

9. 11566041 - Nucleotide prodrug compounds (2023-01-31),

10. 11427550 - 5-fluorouracil compounds (2022-08-30),

11. 11413274 - Methods and compositions associated with the granulocyte colony-stimulating factor receptor (2022-08-16),

12. 11358931 - Selective androgen receptor modulators (SARMs) and uses thereof (2022-06-14),

13. 11278559 - Prodrug compounds and their uses (2022-03-22),

14. 11186593 - Heterocycle amines and uses thereof (2021-11-30),

15. 10874638 - Methods and compositions for modulating hormone levels (2020-12-29),

Title: Lin Zhi: Pioneering Innovations in Nucleotide Prodrug Compounds

Introduction:

In the bustling city of San Diego, California, resides a remarkable inventor named Lin Zhi. With an impressive track record of 119 patents, Lin Zhi has made significant contributions to the field of pharmaceuticals and cancer research. This article will delve into Lin Zhi's latest patents, career highlights, collaborative efforts, and showcase the remarkable work carried out by this inventive individual.

Latest Patents:

Among Lin Zhi's most recent patents, two remarkable pharmaceutical advancements stand out. The first is the groundbreaking discovery of nucleotide prodrug compounds. These compounds have shown great potential in treating various viral infections and associated diseases or conditions. Lin Zhi's innovative approach offers hope for more effective and targeted treatments in the realm of antiviral therapies.

The second notable patent is centered around 5-fluorouracil compounds. Lin Zhi's research has focused on developing derivatives of this compound, known as acetal and hemiaminal ether compounds, for the treatment of liver diseases and different types of cancer. This breakthrough holds promise for improved treatment options and enhanced patient outcomes in these critical areas of medicine.

Career Highlights:

Lin Zhi's exceptional career has been characterized by a strong affiliation with Ligand Pharmaceuticals, Inc., a renowned pharmaceutical company known for its commitment to innovation. Lin Zhi's association with Ligand Pharmaceuticals, Inc. has undoubtedly played a pivotal role in his prolific patent record and groundbreaking discoveries. The collaboration with this esteemed organization has fostered an environment conducive to pushing boundaries and finding novel solutions to complex medical challenges.

Collaborations:

Lin Zhi's groundbreaking work has not been achieved in isolation but has been facilitated by collaborations with esteemed colleagues. Todd Kevin Jones and James Patrick Edwards are two notable coworkers who have played crucial roles in Lin Zhi's research and invention journey. Such collaboration highlights the importance of teamwork and collective knowledge in making significant strides within the field of pharmaceutical research.

Conclusion:

Lin Zhi's contributions to the field of pharmaceutical innovation, particularly in the realm of nucleotide prodrug compounds and 5-fluorouracil derivatives, have opened up new possibilities for the treatment of viral infections, liver diseases, and various types of cancer. His impressive patent portfolio is a testament to his dedication, expertise, and unwavering commitment to improving healthcare outcomes. Through collaborations with notable companies like Ligand Pharmaceuticals, Inc. and colleagues like Todd Kevin Jones and James Patrick Edwards, Lin Zhi's vision and discoveries have paved the way for future advancements in the pharmaceutical industry. As an innovative mind, Lin Zhi continues to inspire and push the boundaries of what is possible in the realm of medical inventions and patents.

Profile summary based on public USPTO records.